Ticker

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Mark Goldsmith sold 120,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider owned 276,698 shares in the

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its concurrent upsized public offerings of 12,147,887 shares of its common stock at a public offering price of $142.00 per share and $500.0 million aggregate principal amount of…

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public offerings of 10,563,381 shares of common stock, at a public offering price of $142.00 per share, for aggregate gross proceeds of approximately $1.5 billion, and $500.0 million…

Revolution Medicines (RVMD) remains a 'Strong Buy' following statistically significant phase 3 RASolute 302 results for daraxonrasib in 2nd-line metastatic PDAC. Company's daraxonrasib achieved median overall survival of 13.2 months vs. 6.7 months for chemotherapy in the ITT population [p < 0.0001]. Expansion opportunities include phase 3 RASolute 303 for 1st-line PDAC and additional late-stage trials in NSCLC and…

Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.